RepliCel Life Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO RepliCel Life Sciences is Andrew Schutte, benoemd in Nov2022, heeft een ambtstermijn van 5.92 jaar. bezit rechtstreeks 26.77% van de aandelen van het bedrijf, ter waarde € 3.34K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 5.9 jaar.

Belangrijke informatie

Andrew Schutte

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2yrs
Eigendom CEO	26.8%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

CEO

Andrew Schutte (34 yo)

2yrs

Tenure

CA$8,917

Compensatie

Mr. Andrew Schutte serves as President, Chief Executive Officer & Director of RepliCel Life Sciences Inc. since November 28, 2022. He served as an Independent Director of RepliCel Life Sciences Inc. since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Schutte	President	2yrs	CA$8.92k	26.77% € 3.3k
Kevin McElwee	Co-Founder & Chief Scientific Officer	13.3yrs	CA$30.00k	2.04% € 255.3
Ben Austring	Chief Legal Officer	2yrs	CA$14.50k	0.49% € 61.6
David Kwok	Chief Financial Officer	1.3yrs	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van P6P2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Schutte	President	5.9yrs	CA$8.92k	26.77% € 3.3k
David Hall	Independent Chairman of the Board	13.9yrs	CA$17.75k	1.35% € 168.2
Jean Krutmann	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Ross Davidson	Chairman of Clinical Advisory Board	11.1yrs	geen gegevens	geen gegevens
Peter Lewis	Independent Director	13.5yrs	CA$14.45k	0.96% € 120.4
R. Buckler	Director	8.8yrs	CA$240.85k	0.010% € 1.3
Gary Boddington	Independent Director	3.4yrs	CA$16.25k	0.48% € 60.5
Jamie MacKay	Director	1.3yrs	geen gegevens	15.44% € 1.9k
Tsukasa Kumai	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Akimichi Morita	Member of Clinical Advisory Board	3.5yrs	geen gegevens	geen gegevens
Kunihiko Suzuki	Senior Strategic Advisor to Directors	3.1yrs	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van P6P2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).

RepliCel Life Sciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

RepliCel Life Sciences Inc., Annual General Meeting, Dec 30, 2024

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

Recent updates

RepliCel Life Sciences Inc., Annual General Meeting, Dec 30, 2024

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.031 loss in 3Q 2022)

First half 2023 earnings released: CA$0.028 loss per share (vs CA$0.054 loss in 1H 2022)

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

First quarter 2023 earnings released: CA$0.018 loss per share (vs CA$0.023 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.02 loss per share (vs CA$0.13 loss in FY 2021)

RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

Third quarter 2022 earnings released: CA$0.031 loss per share (vs CA$0.026 loss in 3Q 2021)

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding

RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise

RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

RepliCel Life Sciences Inc. announced delayed 20-F filing

RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in funding from MainPointe Pharmaceuticals, LLC

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: CA$0.077 loss per share (vs CA$0.026 loss in 1H 2020)

RepliCel Life Sciences Inc. announced that it has received $0.16152 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.111574 million in funding

Replicel Life Sciences Inc. Receiveds the First Units of Its Dermal Injector and Is Nearing Completion

Replicel Life Sciences Inc. Announces Record Year in Patents Granted

RepliCel Life Sciences Inc. announced delayed 20-F filing

Full year 2020 earnings released: CA$0.059 loss per share (vs CA$0.13 loss in FY 2019)

RepliCel Life Sciences Inc. announced that it has received CAD 0.492091 million in funding

New 90-day high: €0.21

Third quarter 2020 earnings released: CA$0.02 loss per share

RepliCel Life Sciences Inc. announced that it expects to receive CAD 2.7 million in funding from MainPointe Pharmaceuticals, LLC

First half earnings released

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.155645 million in funding

RepliCel Life Sciences Inc. announced that it expects to receive CAD 4 million in funding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd